Jakarta, October 3rd, 2022 - PT Kimia Farma Tbk as a part of Pharmaceutical SOE Holding is determined to support the government pharmaceutical and medical devices independence program, in line with Presidential Instruction (Inpres) No. 6/2016 concerning Acceleration of Development of the Pharmaceutical Industry and Medical Devices. Kimia Farma supports the program through the development and manufacture of Pharmaceutical Raw Materials or “Bahan Baku Obat (BBO)” domestically by PT Kimia Farma Sungwun Pharmacopia (KFSP) as Kimia Farma’s subsidiary.
PT Kimia Farma Tbk collaborates with Sung Wun Pharmacopia Co, Ltd. from South Korea to build and enhance the capability of a qualified BBO development and technological research in order to produce BBO that meets both national and international quality standards. The BBO manufacturing facility that was completed in 2018 continues to innovate to create national health resilience through BBO manufacturing.
To date, PT Kimia Farma Sungwun Pharmacopia has obtained the certificate of Good Manufacturing Practices of Active Pharmaceutical Ingredients from the Indonesian Food and Drug Authority (BPOM). The development of BBO is done in line with the government program and national priority needs. Until 2022, KFSP has produced 12 BBOs that are GMP certified from BPOM and are ready to be used by all pharmaceutical industry in Indonesia that include:
3 Anticholesterol BBOs which are Simvastatin, Atorvastatin, and Rosuvastatin
1 Antiplatelet BBO for heart drug which is Clopidogrel
2 Antivirus BBO which are Entecavir and Remdesivir
4 Antiretroviral (ARV) BBOs for HIV AIDS which are Tenofovir, Lamivudin, Zidovudin, and Efavirenz
1 BBO for diarrhea which is Attapulgite
1 BBO for antiseptic and disinfectant which is Lodium Povidon
These BBOs have obtained halal certificates from Indonesian Ulema Council (MUI) to support the implementation of Law No. 33/2014 concerning Halal Product Assurance.